THL – TorHoerman Law

Invokanaand other dangerous SGLT-2 inhibitors

Invokana Lawsuit

Patients who have previously been prescribed Invokana — or similar SGLT-2 inhibitor — and been injured by the drug may be eligible to participate in an Invokana lawsuit.

What is Invokana?

Invokana, approved by the U.S. Food and Drug Administration (FDA) in 2013, is part of a class of Type 2 diabetes drugs called sodium-glucose cotransporter-2 (SGLT-2) inhibitors. SGLT2 is a protein in humans that facilitates glucose reabsorption in the kidneys, and SGLT2 inhibitors block the reabsorption of glucose in the kidneys, increase glucose excretion, and in turn lower blood glucose levels. SGLT-2 inhibitors are commonly used to treat adults with Type-2 diabetes.

Invokana Injuries & Side Effects

However, despite its notable ability to control blood sugar levels, Invokana has some potentially serious side effects, including:

  • Kidney damage – Kidney failure occurs when the kidneys stop functioning without the help of dialysis or a kidney transplant. Kidneys help filter waste products from the blood, so when they stop functioning properly, electrolytes, fluids, and waste products build up in the body and cause abnormal heart rhythms, confusion, shortness of breath, weakness, and death.
  • Amputations – Clinical trials have found that Invokana users are twice as likely to suffer from lower limb amputation as compared to patients using a placebo. The risks are even higher for patients who have already suffered from a previous amputation. Invokana users should look for signs – infections in lower limbs, tenderness, sores – talk to a doctor right away if you experience any of these symptoms.
  • Ketoacidosis – When the body is unable to produce enough insulin, ketoacidosis develops. Without enough insulin, the body breaks down fat as an alternative source of energy, which in turn produces a buildup of toxic acids in the bloodstream known as ketones. When untreated, excess ketones in the blood result in ketoacidosis, which can lead to diabetic coma, hospitalization, and death.
  • Myocardial infarction (heart attack) – The heart requires a constant supply of oxygen and nutrients delivered in the blood by two large, branching coronary arteries to the heart muscle. If one of the arteries or branches becomes blocked, a portion of the heart is starved of oxygen and a condition called cardiac ischemia occurs. If cardiac ischemia lasts too long, the starved heart tissue dies, and a heart attack, also known as myocardial infarction, occurs.

Researchers have also expressed concerns about unsafe increases in low blood pressure symptoms, urinary infections, breast and bladder cancer, pancreatitis, yeast infections, and bone fractures.

Follow-up SGLT-2 inhibitors

Following the release of Invokana, the FDA approved drugs in the same SGLT-2 class. All though they carry a different brand name, these follow-up drugs carry the same risks and warnings as Invokana and Invokamet. These follow-up SGLT-2 inhibitors also include:

  • Jardiance
  • Farxiga
  • Xigduo XR
  • Glyxambi

Invokana Timeline

March 2013, the FDA approves Invokana for market

May 2015, the FDA issues a drug safety communication stating that Invokana, Farxiga, and Jardiance may lead to ketoacidosis, and highlighted 20 cases of acidosis in patients treated with SGLT2 inhibitors from March 2013 to June 2014.

September 2015, the FDA revises Invokana and Invokamet labels to include information about the risk of bone fracture.

May 2016, the FDA issues a consumer safety alert for SLGT-2 inhibitors.

June 2016, the FDA introduces new warning for Invokana, Invokamet, Farxiga, and Xigduo XR, linking the SGLT-2 inhibitors to reports of acute kidney injury that required hospitalization in some cases.

May 2017, the FDA issues a black box label for Invokana and other SGLT2 inhibitors warning consumers of the higher risks of lower limb amputation for patients using SGLT2 inhibitors. The risks of amputation were twice as high for patients using Invokana or similar SGLT2 inhibitors.

 

Current Invokana lawsuits

 A conglomeration of patients has already filed a multi-district Invokana lawsuit against the manufacturer, Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson.

The Invokana lawsuit claims:

  • Is a defective and unreasonably dangerous product
  • Puts patients at risk of amputation, kidney damage, ketoacidosis, and myocardial infarction.
  • Manufacturer, Janssen Pharmaceutical, failed to warn consumers of these known risks.
  • Janssen failed to test Invokana for all possible side effects.
  • The company also held in-house data, which indicated the dangers of the drug, from the FDA and consumers.

If you or a loved one was taking Invokana (or a similar SGLT-2) to treat Type-2 or Type-1 diabetes and suffered injuries from the drug, you may be entitled to compensation for your damages.

Contact the office of TorHoerman Law, for a free no-obligation Invokana case assessment today.

No-Obligation Free Consultation

Contact us by phone at (618) 656-4400 or email us below.

Sidebar Contact

Your information will be used only so that we may contact you to evaluate your case. Your contact information will never be shared or sold to anyone other than TorHoerman Law.